My Treatment Approach: Bispecifics in Multiple Myeloma: Translating Evidence to Clinical Practice

Expert hematologist-oncologist Adriana Rossi, MD, shares a real-world patient scenario of triple-class refractory multiple myeloma managed with novel bispecific antibody therapy.

Shared insight on factors that help to determine optimal therapy for patients diagnosed with triple-class refractory multiple myeloma.

Expert perspectives on the MajesTEC-1 trial, a study of BCMA- and CD3-targeted agent teclistamab in relapsed/refractory multiple myeloma.

Moving on to the second clinical scenario of multiple myeloma, Luciano Costa, MD, details his care of a heavily pretreated patient.

Comprehensive discussion on the MonumenTAL-1 trial of talquetamab, a GPRC5D- and CD3-targeted agent, in the setting of relapsed/refractory multiple myeloma.

In light of emerging bispecific and CAR T-cell therapies in multiple myeloma, experts consider how they might optimally sequence treatment.

Luciano Costa, MD, and Adriana Rossi, MD, consider the possibility of earlier-line bispecific and CAR T-cell therapies in multiple myeloma.

Closing out their discussion on bispecifics in multiple myeloma, expert hematologist-oncologists share practical advice for community physicians alongside their hopes for the future.